NCT03179436 : A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab for Subjects With Advanced Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Bowel (colorectum),Brain and spinal cord,Breast,CUP,Female reproductive organs,Head and neck,Lung,Sarcoma,Skin,Stomach and upper gastrointestinal tract,Urinary systemAdrenocortical carcinoma,Anus,Basal cell carcinoma,Bile duct,Bladder,Bone,Brain,Brain stem,Breast,Central Nervous System,Cervix,Chondrosarcoma,Colon,Colorectum,Cutaneous Squamous Cell Carcinoma (CSCC),Endometrium,Ewing's Sarcoma,Fallopian tube,Gallbladder,Gastrointestinal stromal tumour (GIST),Germ cell tumour,Glioblastoma (GBM) ,Glioma,Head and neck,Kidney,Liver,Lung,Medullablastoma,Meningioma,Neuroendocrine tumours,Non-Small Cell Lung Cancer,Nose (nasopharynx),Oesophagus,Oral cavity,Oropharynx,Osteosarcoma,Ovary,Pancreas,Paroxysmal Nocturnal Hemoglobinuria (PNH),Penis,Peritoneal,Polycythaemia vera,Prostate,Rectum,Renal cell carcinoma,Rhabdomyosarcoma,Salivary glands,Sarcoma,Small Cell Lung Cancer,Soft Tissue Sarcoma,Spinal Cord,Squamous cell carcinoma ,Stomach,Synovial Sarcoma,Testis,Throat (hypopharynx),Thyroid,Urinary tract,Urothelial,Uterus,Vagina,Voice box (larynx),Vulva,Wilm's tumour

Trial Overview Read MoreRead more

This phase I trial is evaluating the safety and effectiveness of increasing doses of an immunotherapy drug (MK-1308) given in combination with another immunotherapy drug (Pembrolizumab) for the treatment of patients with advanced solid tumours.
 

This trial is treating patients with Advanced solid tumours.

This is a systemic treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab for Subjects With Advanced Solid Tumors

Commercial Sponsor

Merck

Summary

Participants eligible for this trial will be assigned to either a Dose Escalation or Dose Confirmation phase of the trial. Patients in the Dose Escalation phase of the trial will receive MK-1308 on Day 1 of the first cycle, MK-1308 and pembrolizumab of Day 1 of cycles 2-5 and pembrolizumab for on Day 1 of the remaining cycles. Patients in the Dose Confirmation phase of the trial will receive MK-1803 and pembrolizumab on Day 1 of all cycles. Patients in both trial phases will be treated for up to 35 cycles.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Medical Oncology
Prahran
Ms Jacquie Dixon
Ja.Dixon@alfred.org.au
03 9076 7464

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next